MiRNA Influences in NRF2 Pathway Interactions within Cancer Models

Journal of Nucleic Acids

Volumn 2015, Issue , 2015, Pages

  Ayers, Duncan ^a,b   Baron, Byron ^a   Hunter, Therese ^a  

^a UNIVERSITY OF MALTA   (Malta)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; MICRORNA; TRANSCRIPTION FACTOR NRF2;

ARTICLE; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RESISTANCE; GENE CONTROL; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; INTRACELLULAR SIGNALING; MULTIDRUG RESISTANCE; NEUROBLASTOMA CELL LINE; NON SMALL CELL LUNG CANCER; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION;

EID: 84940416445     PISSN: 20900201     EISSN: 2090021X     Source Type: Journal    
DOI: 10.1155/2015/143636     Document Type: Article

References (37)

1. T. T. Cao, L. Ma, G. Kandpal, L. Warren, J. F. Hess, and G. R. Seabrook, "Increased nuclear factor-erythroid 2 p45-related factor 2 activity protects SH-SY5Y cells against oxidative damage," Journal of Neurochemistry, vol. 95, no. 2, pp. 406-417, 2005.
2. N. Wakabayashi, S. L. Slocum, J. J. Skoko, S. Shin, and T. W. Kensler, "When NRF2 talks, who's listening?" Antioxidants & Redox Signaling, vol. 13, no. 11, pp. 1649-1663, 2010.
3. H. K. Bryan, A. Olayanju, C. E. Goldring, and B. K. Park, "The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation," Biochemical Pharmacology, vol. 85, no. 6, pp. 705-717, 2013.
4. K. M. Kanninen, Y. Pomeshchik, H. Leinonen, T. Malm, J. Koistinaho, and A.-L. Levonen, "Applications of the Keap1-Nrf2 system for gene and cell therapy," Free Radical Biology and Medicine, 2015.
5. S. Murakami and H. Motohashi, "Roles of NRF2 in cell proliferation and differentiation," Free Radical Biology and Medicine, 2015.
6. Y.-Z. Gu, J. B. Hogenesch, and C. A. Bradfield, "The PAS superfamily: sensors of environmental and developmental signals," Annual Reviewof Pharmacology and Toxicology, vol. 40, pp. 519-561, 2000.
7. G.-H. Liu, J. Qu, and X. Shen, "NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1783, no. 5, pp. 713-727, 2008.
8. K. Iida, K. Itoh, J. M. Maher et al., "Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis," Carcinogenesis, vol. 28, no. 11, pp. 2398-2403, 2007.
9. N. Wakabayashi, S. Shin, S. L. Slocum et al., "Regulation of Notch1 signaling by Nrf2: implications for tissue regeneration," Science Signaling, vol. 3, no. 130, p. ra52, 2010.
10. R. C. Lee, R. L. Feinbaum, and V. Ambros, "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14," Cell, vol. 75, no. 5, pp. 843-854, 1993.
11. S. Griffiths-Jones, H. K. Saini, S. van Dongen, and A. J. Enright, "miRBase: tools for micro RNA genomics," Nucleic Acids Research, vol. 36, no. 1, pp.D154-D158, 2008.
12. M. Metzler, M. Wilda, K. Busch, S. Viehmann, and A. Borkhardt, "High expression of precursor micro RNA-155/BIC RNA in children with Burkitt lymphoma," Genes Chromosomes and Cancer, vol. 39, no. 2, pp. 167-169, 2004.
13. N. H. Foley, I.M. Bray, A. Tivnanet al., "Micro RNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2," Molecular Cancer, vol. 9, article 83, 2010.
14. P. Mestdagh, E. Fredlund, F. Pattyn et al., "MYCN/c-MYCinduced micro RNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors," Oncogene, vol. 29, no. 9, pp. 1394-1404, 2010.
15. A. J. Lowery, N. Miller, R. M. Dwyer, and M. J. Kerin, "Dysregulated miR-183 inhibits migration in breast cancer cells," BMC Cancer, vol. 10, article 502, 2010.
16. H. Osada and T. Takahashi, "let-7 and miR-17-92: small-sized major players in lung cancer development," Cancer Science, vol. 102, no. 1, pp. 9-17, 2011.
17. A. Carta, R. Chetcuti, and D. Ayers, "An introspective update on the influence of miRNAs in breast carcinoma and neuroblastoma chemoresistance," Genetics Research International, vol. 2014, Article ID 743050, 13 pages, 2014.
18. N. M. Shah, S. A. Rushworth, M. Y. Murray, K. M. Bowles, and D. J. MacEwan, "Understanding the role of NRF2-regulated miRNAs in human malignancies," Oncotarget, vol. 4, no. 8, pp. 1130-1142, 2013.
19. D. Türei, D. Papp, D. Fazekas et al., "NRF2-ome: an integrated web resource to discover protein interaction and regulatory networks of NRF2," Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID737591, 9 pages, 2013.
20. B. N. Chorley, M. R. Campbell, X. Wang et al., "Identification of novel NRF2-regulated genes by ChiP-Seq: influence on retinoid X receptor alpha," Nucleic Acids Research, vol. 40, no. 15, pp. 7416-7429, 2012.
21. C. Luna, G. Li, J. Qiu, D. L. Epstein, and P. Gonzalez, "Role of miR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress," Molecular Vision, vol. 15, pp. 2488-2497, 2009.
22. C. Sangokoya, M. J. Telen, and J.-T. Chi, "microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease," Blood, vol. 116, no. 20, pp. 4338-4348, 2010.
23. M. Yang, Y. Yao, G. Eades, Y. Zhang, and Q. Zhou, "MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism," Breast Cancer Research and Treatment, vol. 129, no. 3, pp. 983-991, 2011.
24. B. Singh, A. M. Ronghe, A. Chatterjee, N. K. Bhat, and H. K. Bhat, "MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis," Carcinogenesis, vol. 34, no. 5, pp. 1165-1172, 2013.
25. M. Narasimhan, D. Patel, D. Vedpathak, M. Rathinam, G. Henderson, and L. Mahimainathan, "Identification of novel microRNAs in post-transcriptional control of Nrf2 expression and redox homeostasis in neuronal, SH-SY5Y cells," PLoS ONE, vol. 7, no. 12, Article ID e51111, 2012.
26. A. Singh, C. Happel, S. K. Manna et al., "Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis," The Journal of Clinical Investigation, vol. 123, no. 7, pp. 2921-2934, 2013.
27. N. M. Shah, L. Zaitseva, K. M. Bowles, D. J. MacEwan, and S. A. Rushworth, "NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival," Cell Death and Differentiation, vol. 22, no. 4, pp. 654-664, 2015.
28. M. S. Joo, C. G. Lee, J. H. Koo, and S. G. Kim, "miR-125b transcriptionally increased by Nrf2 inhibits AhR repressor, which protects kidney from cisplatin-induced injury," Cell Death and Disease, vol. 4, no. 10, article e899, 2013.
29. A. Buhagiar and D. Ayers, "Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma," Analytical Cellular Pathology, vol. 2015, Article ID 150634, 8 pages, 2015.
30. D. Ayers and A. Nasti, "Utilisation of nanoparticle technology in cancer chemoresistance," Journal of Drug Delivery, vol. 2012, Article ID 265691, 12 pages, 2012.
31. L. Shi, L. Wu, Z. Chen et al., "MiR-141 activates Nrf2-dependent antioxidant pathway via down-regulating the expression of keap1 conferring the resistance of hepatocellular carcinoma cells to 5-fluorouracil," Cellular Physiology and Biochemistry, vol. 35, no. 6, pp. 2333-2348, 2015.
32. L. Shi, Z.-G. Chen, L.-L. Wu et al., "miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway," Asian Pacific Journal of Cancer Prevention, vol. 15, no. 23, pp. 10439-10444, 2014.
33. T. Murray-Stewart, C. L. Hanigan, P. M. Woster, L. J. Marton, and R. A. Casero Jr., "Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism," Molecular Cancer Therapeutics, vol. 12, no. 10, pp. 2088-2099, 2013.
34. G. Eades, M. Yang, Y. Yao, Y. Zhang, and Q. Zhou, "miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells," Journal of Biological Chemistry, vol. 286, no. 47, pp. 40725-40733, 2011.
35. M. A. Cortez, D. Valdecanas, X. Zhang et al., "Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer," Molecular Therapy, vol. 22, no. 8, pp. 1494-1503, 2014.
36. A. Loboda, A. Jozkowicz, and J. Dulak, "HIF-1 versus HIF-2-is one more important than the other?" Vascular Pharmacology, vol. 56, no. 5-6, pp. 245-251, 2012.
37. A. E. Wagner, C. Boesch-Saadatmandi, J. Dose, G. Schultheiss, and G. Rimbach, "Anti-inflammatory potential of allyl-isothiocyanate-role of nrf2, nf-κB and microrna-155," Journal of Cellular and Molecular Medicine, vol. 16, no. 4, pp. 836-843, 2012.